Fenofibrate/Metformin Hydrochloride

非诺贝特/盐酸二甲双胍

Report date: 2023/04/25 13:50:10

Base Information

Drug NameFenofibrate/Metformin Hydrochloride
Drug Alias Name盐酸二甲双胍/非诺贝特Metformin Hydrochloride/Fenofibrate非诺贝特+二甲双胍Fenomax/Metformin HydrochlorideFenofibrate/Metformin +[7] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptorProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDyslipidemiasDiabetes Mellitus, Type 2Glucose Metabolism Disorders +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUkraineSlovakia +[13] 
CombinationsYes Metformin HydrochlorideFenofibrate
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFournier Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSolvay Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsDyslipidemiasDiabetes Mellitus, Type 2Glucose Metabolism Disorders +[4] 

Other Information

ATC CodeN/A
Related LinksN/A